ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients with Merkel cell carcinoma after surgery. Though recurrence rates overall ...

Non-melanoma skin cancer includes BCC, SCC, and the rare MCC, with BCC being the most common and MCC the most aggressive. Diagnosis involves skin examination and biopsy, with additional tests for MCC ...

Merkel cell polyomavirus is one of seven viruses known to cause cancer in humans. Infection with this virus is asymptomatic, but, rarely, it can lead to the development of Merkel cell carcinoma (MCC), ...

Patients with resected Merkel cell carcinoma residing in Medicaid expansion states had greater survival rates than those in nonexpansion states.

Huntington’s disease as a protective factor for non-melanoma skin cancer: A retrospective cohort study using the TriNetX dataset. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.